Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
Document Type
Journal Article
Publication Date
2-9-2020
Journal
BMJ Open
Volume
10
Issue
2
Inclusive Pages
e034629
DOI
10.1136/bmjopen-2019-034629
APA Citation
George, P., Dasyam, N., Giunti, G., Mester, B., Bauer, E., Andrews, B., Perera, T., Ostapowicz, T., Frampton, C., Li, P., Ritchie, D., Bollard, C. M., Hermans, I., & Weinkove, R. (2020). Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).. BMJ Open, 10 (2). http://dx.doi.org/10.1136/bmjopen-2019-034629
Peer Reviewed
1
Open Access
1
- Citations
- Citation Indexes: 45
- Patent Family Citations: 1
- Policy Citations: 1
- Usage
- Abstract Views: 20
- Captures
- Readers: 80
- Mentions
- References: 1
